 Robert Belknap
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 27 | 2023 | 64 | 8.940 |
Why?
| | Antitubercular Agents | 18 | 2023 | 169 | 4.580 |
Why?
| | Tuberculosis | 15 | 2023 | 241 | 4.530 |
Why?
| | Isoniazid | 13 | 2023 | 52 | 4.290 |
Why?
| | Mycobacterium tuberculosis | 7 | 2021 | 268 | 2.400 |
Why?
| | Rifampin | 9 | 2023 | 68 | 2.120 |
Why?
| | Directly Observed Therapy | 4 | 2021 | 14 | 1.840 |
Why?
| | Interferon-gamma Release Tests | 13 | 2023 | 26 | 1.770 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2019 | 112 | 1.770 |
Why?
| | Tuberculin Test | 13 | 2023 | 32 | 1.520 |
Why?
| | Mass Screening | 4 | 2020 | 1011 | 0.940 |
Why?
| | Medication Adherence | 3 | 2018 | 537 | 0.840 |
Why?
| | Drug Therapy, Combination | 10 | 2023 | 959 | 0.790 |
Why?
| | Sputum | 3 | 2019 | 285 | 0.760 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2019 | 46 | 0.730 |
Why?
| | Drug Administration Schedule | 6 | 2021 | 721 | 0.690 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 87 | 0.640 |
Why?
| | Rifamycins | 1 | 2018 | 5 | 0.630 |
Why?
| | Emigrants and Immigrants | 3 | 2020 | 108 | 0.620 |
Why?
| | Self Administration | 1 | 2017 | 123 | 0.570 |
Why?
| | Health Personnel | 2 | 2019 | 575 | 0.520 |
Why?
| | Early Diagnosis | 1 | 2016 | 218 | 0.490 |
Why?
| | Immunologic Factors | 1 | 2016 | 221 | 0.480 |
Why?
| | Humans | 45 | 2023 | 115219 | 0.470 |
Why?
| | United States | 11 | 2023 | 12256 | 0.440 |
Why?
| | Osteomyelitis | 2 | 2012 | 103 | 0.430 |
Why?
| | Proteome | 1 | 2016 | 339 | 0.430 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2019 | 42 | 0.430 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1397 | 0.410 |
Why?
| | Diabetic Foot | 1 | 2012 | 22 | 0.410 |
Why?
| | Limb Salvage | 1 | 2012 | 52 | 0.400 |
Why?
| | Biosensing Techniques | 1 | 2013 | 99 | 0.390 |
Why?
| | Students | 1 | 2016 | 499 | 0.380 |
Why?
| | Streptomycin | 1 | 2011 | 13 | 0.380 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.380 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 23 | 0.370 |
Why?
| | HIV Infections | 5 | 2021 | 2470 | 0.370 |
Why?
| | Proteomics | 1 | 2016 | 844 | 0.370 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 61 | 0.350 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 225 | 0.340 |
Why?
| | Bacteremia | 1 | 2011 | 159 | 0.330 |
Why?
| | Sensitivity and Specificity | 5 | 2020 | 1717 | 0.320 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.310 |
Why?
| | Adult | 15 | 2021 | 30708 | 0.300 |
Why?
| | Renal Dialysis | 1 | 2011 | 369 | 0.290 |
Why?
| | Clostridium Infections | 1 | 2008 | 56 | 0.290 |
Why?
| | Biomarkers | 1 | 2016 | 3421 | 0.270 |
Why?
| | Middle Aged | 14 | 2023 | 26872 | 0.270 |
Why?
| | Anti-Bacterial Agents | 5 | 2013 | 1481 | 0.270 |
Why?
| | Female | 19 | 2023 | 59717 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 1214 | 0.260 |
Why?
| | Male | 16 | 2021 | 55811 | 0.220 |
Why?
| | Staphylococcal Infections | 3 | 2013 | 337 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 242 | 0.200 |
Why?
| | Fractures, Open | 2 | 2013 | 26 | 0.200 |
Why?
| | Sepsis | 1 | 2008 | 508 | 0.200 |
Why?
| | Adolescent | 9 | 2021 | 17887 | 0.200 |
Why?
| | Health Systems Plans | 1 | 2020 | 3 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1138 | 0.180 |
Why?
| | Substance-Related Disorders | 1 | 2008 | 945 | 0.170 |
Why?
| | Self Report | 1 | 2023 | 699 | 0.160 |
Why?
| | Treatment Failure | 2 | 2018 | 332 | 0.160 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 1268 | 0.160 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 34 | 0.160 |
Why?
| | Public Health | 2 | 2013 | 435 | 0.150 |
Why?
| | Urban Health Services | 1 | 2018 | 61 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2021 | 12596 | 0.150 |
Why?
| | Antibiotics, Antitubercular | 1 | 2017 | 35 | 0.150 |
Why?
| | Aged | 6 | 2021 | 19135 | 0.140 |
Why?
| | Drug Monitoring | 1 | 2018 | 184 | 0.140 |
Why?
| | Child, Preschool | 5 | 2021 | 9123 | 0.140 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2016 | 34 | 0.140 |
Why?
| | Prospective Studies | 5 | 2023 | 6245 | 0.140 |
Why?
| | Comorbidity | 2 | 2019 | 1458 | 0.140 |
Why?
| | Young Adult | 5 | 2019 | 10519 | 0.130 |
Why?
| | Reminder Systems | 1 | 2017 | 161 | 0.130 |
Why?
| | Urban Population | 1 | 2018 | 402 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 295 | 0.130 |
Why?
| | Text Messaging | 1 | 2017 | 154 | 0.120 |
Why?
| | False Positive Reactions | 2 | 2014 | 109 | 0.120 |
Why?
| | Odds Ratio | 1 | 2018 | 958 | 0.120 |
Why?
| | Population Surveillance | 1 | 2018 | 392 | 0.120 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 288 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2018 | 9151 | 0.110 |
Why?
| | Universities | 1 | 2016 | 340 | 0.110 |
Why?
| | Infant | 3 | 2020 | 7966 | 0.110 |
Why?
| | Prosthesis-Related Infections | 1 | 2013 | 70 | 0.110 |
Why?
| | Vancomycin | 1 | 2013 | 75 | 0.100 |
Why?
| | Debridement | 1 | 2012 | 75 | 0.100 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 372 | 0.100 |
Why?
| | Risk Factors | 4 | 2018 | 8658 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 2981 | 0.090 |
Why?
| | Uganda | 2 | 2021 | 70 | 0.090 |
Why?
| | Mycobacterium leprae | 1 | 2010 | 7 | 0.090 |
Why?
| | Leprosy | 1 | 2010 | 10 | 0.090 |
Why?
| | Bayes Theorem | 2 | 2023 | 331 | 0.090 |
Why?
| | Glycolipids | 1 | 2010 | 35 | 0.090 |
Why?
| | Infant, Newborn | 2 | 2018 | 5052 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 731 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2011 | 96 | 0.090 |
Why?
| | Drug Synergism | 1 | 2011 | 317 | 0.090 |
Why?
| | Antigens, Bacterial | 1 | 2010 | 112 | 0.090 |
Why?
| | Antibodies, Bacterial | 1 | 2010 | 119 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2013 | 744 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4430 | 0.080 |
Why?
| | Child | 4 | 2019 | 18466 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1130 | 0.080 |
Why?
| | Orthopedics | 1 | 2011 | 122 | 0.080 |
Why?
| | Primary Health Care | 1 | 2018 | 1514 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 386 | 0.070 |
Why?
| | Age Distribution | 1 | 2008 | 341 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 818 | 0.070 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 81 | 0.070 |
Why?
| | Incidence | 2 | 2013 | 2324 | 0.070 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 99 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2011 | 668 | 0.060 |
Why?
| | Body Mass Index | 1 | 2013 | 1968 | 0.060 |
Why?
| | Infliximab | 1 | 2005 | 94 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1356 | 0.060 |
Why?
| | Mycobacterium avium | 1 | 2004 | 21 | 0.060 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 18 | 0.060 |
Why?
| | Peritonitis | 1 | 2004 | 76 | 0.050 |
Why?
| | Network Meta-Analysis | 1 | 2023 | 15 | 0.050 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2004 | 63 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 4917 | 0.050 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 6 | 0.040 |
Why?
| | HIV | 1 | 2021 | 208 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 155 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 279 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1002 | 0.040 |
Why?
| | Colorado | 2 | 2018 | 4099 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 517 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 338 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1816 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1860 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2257 | 0.030 |
Why?
| | Premedication | 1 | 2013 | 36 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1748 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2390 | 0.030 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.020 |
Why?
| | Fracture Fixation, Internal | 1 | 2013 | 195 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3023 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 141 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1377 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 796 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1150 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1237 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2388 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 5525 | 0.020 |
Why?
| | Mice | 1 | 2021 | 14934 | 0.020 |
Why?
| | Immunocompetence | 1 | 2004 | 40 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 4419 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6157 | 0.010 |
Why?
| | Animals | 1 | 2021 | 31884 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2552 | 0.010 |
Why?
|
|
Belknap's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|